Tenon Medical Announces Fusion Results in First Patients Reaching 12-Month Follow Up in an IRB Approved, Multi-Centered, Post-Market Study Utilizing the Catamaran SI Joint Fusion System

Tenon Medical, Inc. (NASDAQ:TNON) ("Tenon" or the "Company"), a company transforming care for patients suffering with certain sacroiliac joint disorders, today announced significant progress in the post-market study utilizing the Company's Catamaran® SI Joint Fusion System. The study is a prospective, multi-center, single-arm post market study evaluating the clinical outcomes of patients with sacroiliac joint disruptions or degenerative sacroil itis treated with the Catamaran SI Joint Fusion System. Patients wil be evaluated for a period of up to 24 months reviewing various patient reported outcomes, radiographic assessments, and adverse events. Study enrolment is expected to be finalized in the coming quarter. The preliminary results demonstrate a robust fusion response at 12-months post-procedure based on the independent radiologist review of computed tomography (CT) scans of the SI joint in 100% of the initial cohort of treated patients that have reached the 12-month folow-up. Additionaly, these initial results demonstrate marked improvements in pain scores and disability. These preliminary results also reflect high patient satisfaction ratings specific to the procedure and outcomes.